T. André Et Al. , "KEYSTEP-008: phase II trial of pembrolizumab-based combination in MSI-H/dMMR metastatic colorectal cancer," Future Oncology , vol.19, no.37, pp.2445-2452, 2023
André, T. Et Al. 2023. KEYSTEP-008: phase II trial of pembrolizumab-based combination in MSI-H/dMMR metastatic colorectal cancer. Future Oncology , vol.19, no.37 , 2445-2452.
André, T., Pietrantonio, F., Avallone, A., Gumus, M., Wyrwicz, L., Kim, J. G., ... YALÇIN, Ş.(2023). KEYSTEP-008: phase II trial of pembrolizumab-based combination in MSI-H/dMMR metastatic colorectal cancer. Future Oncology , vol.19, no.37, 2445-2452.
André, Thierry Et Al. "KEYSTEP-008: phase II trial of pembrolizumab-based combination in MSI-H/dMMR metastatic colorectal cancer," Future Oncology , vol.19, no.37, 2445-2452, 2023
André, Thierry Et Al. "KEYSTEP-008: phase II trial of pembrolizumab-based combination in MSI-H/dMMR metastatic colorectal cancer." Future Oncology , vol.19, no.37, pp.2445-2452, 2023
André, T. Et Al. (2023) . "KEYSTEP-008: phase II trial of pembrolizumab-based combination in MSI-H/dMMR metastatic colorectal cancer." Future Oncology , vol.19, no.37, pp.2445-2452.
@article{article, author={Thierry André Et Al. }, title={KEYSTEP-008: phase II trial of pembrolizumab-based combination in MSI-H/dMMR metastatic colorectal cancer}, journal={Future Oncology}, year=2023, pages={2445-2452} }